BPC-157 TB-500 is a two-peptide repair blend with strong single-compound data and no combination trial on record.

Two peptides, one repair rationale

BPC-157 TB-500 is the research-community name for a two-peptide tissue-repair blend — marketed and discussed as the "Wolverine" stack — that pairs BPC-157 with TB-500. It is not a single chemical entity. It has no molecular weight, CAS number, or approved indication of its own; the values below describe its two constituents ^[1][3].

The first channel is BPC-157 (Body Protection Compound 157), a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419.5 Da) derived from a protein found in human gastric juice. In rodent tissue-repair models it accelerated healing of a fully transected Achilles tendon across biomechanical, functional, and microscopic measures at 10 microg/kg ^[1], and it is pro-angiogenic by up-regulating VEGFR2 with downstream Akt-eNOS signaling ^[2].

The second channel is TB-500, a synthetic N-acetylated heptapeptide (Ac-LKKTETQ, ~889.0 Da) corresponding to the actin-binding region — residues 17-23 — of the 43-residue protein Thymosin Beta-4. Its LKKTETQ motif binds monomeric G-actin in a 1:1 complex and sequesters it, regulating the cytoskeletal dynamics that drive cell migration ^[3][4]. One caveat carries through everything that follows: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the 7-mer ^[4][5].

What is the Wolverine peptide blend?

Wolverine is a research-community name for a two-peptide pairing of BPC-157 and TB-500, sold and discussed as a tissue-repair stack. It is not a single chemical entity, has no single molecular weight or CAS number, and is not an approved product anywhere ^[1][3].

The pairing logic is complementary mechanisms. BPC-157 occupies the cytoprotective and pro-angiogenic node of a tissue-repair network — VEGFR2-Akt-eNOS angiogenesis, nitric-oxide modulation, and growth-hormone-receptor-driven fibroblast proliferation ^[2]. TB-500 occupies the cytoskeletal node — actin sequestration that regulates cell migration, re-epithelialization, and progenitor mobilization ^[3][4]. The two are described as acting through complementary but largely non-overlapping pathways. That description is the entire basis of the "synergy" claim, and it is a mechanistic extrapolation, not a finding from a controlled combination study. The reasoning is unpacked in the BPC-157 TB-500 synergy research.

What is the Wolverine peptide blend?

Wolverine is a two-peptide pairing of BPC-157 and TB-500, named in the research community and marketed as a tissue-repair stack. It is not a single molecule, carries no CAS number or molecular weight of its own, and has no approved therapeutic indication. Commercial vials are commonly labeled with a combined per-vial mass (for example, 10 mg + 10 mg), but composition and ratio are not standardized ^[3].

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region, residues 17-23, of Thymosin Beta-4 ^[1][3]. The Wolverine blend pairs the two as a tissue-repair stack; it is not a single chemical entity or an approved product.

What is the BPC-157 and TB-500 blend used for in research?

Its two components occupy complementary nodes of a tissue-repair network in preclinical work: BPC-157 for cytoprotection, angiogenesis, and tendon/ligament repair in rodent models ^[1][2], and TB-500 / Thymosin Beta-4 for cell migration, re-epithelialization, and wound healing in animal and biochemical models ^[3][4]. The assembled blend itself has not been tested in a controlled study ^[6].

The Wolverine Stack: BPC-157 and TB-500 Combined

The BPC-157 TB-500 stack assembles two separately characterized repair signals into one vial. On the evidence, the two halves are unequal in maturity but equal in one respect: neither has been tested as part of the blend.

BPC-157's record is the more developed of the two. A 2025 systematic review of BPC-157 in orthopaedic sports medicine catalogued 36 studies — 35 preclinical, exactly one human — found "no clinical safety data," and rated the evidence at the lowest tiers (level IV-V) ^[6]. A 2025 narrative review reached the same conclusion: broad preclinical support, only three small human pilot studies, and a recommendation to treat BPC-157 as investigational given regulatory controversy and non-regulated availability ^[8].

TB-500's record leans on its parent protein. Thymosin Beta-4 is a multifunctional regenerative peptide that binds actin, promotes cell migration, reduces myofibroblast number, and promotes angiogenesis ^[4]. The synthetic heptapeptide actually sold as TB-500 was characterized as the Ac-17-23 fragment for doping-control reference ^[5] — but the bulk of the efficacy literature was generated with the full-length protein, not the fragment.

The combined product sits on top of both records without adding to either. No peer-reviewed study has tested the assembled BPC-157 plus TB-500 blend for any indication ^[6]. The 2026 Sports Medicine review of approved and unapproved musculoskeletal peptides lists both BPC-157 and TB-500, notes favorable animal-model outcomes, and cautions that rigorous human safety data are scarce, with potential for serious harm ^[7]. For the side-by-side mechanism breakdown, see BPC-157 and TB-500 mechanisms; for the constituent dose figures, see BPC-157 TB-500 dosage in animal studies.

Read the channels separately

The honest way to read this blend is one channel at a time. A finding from BPC-157 is a BPC-157 finding; a finding from Thymosin Beta-4 is a Thymosin Beta-4 finding; and a claim about the two given together is, at present, an empty readout.

This terminal logs each constituent against its own studies and flags every blend-level claim as having no controlled data behind it. The combination's human efficacy and safety are unproven, and the principal theoretical safety concern — a pro-angiogenic, pro-migratory tumor signal associated with Thymosin Beta-4 — is the kind of signal that compounds, not cancels, when two pro-repair peptides are combined ^[4]. That concern, and the WADA and FDA status of both peptides, are detailed in side effects and the tumor-signal concern and in Wolverine legal status and FDA 503A category.

What follows across this site is the record itself: the mechanism literature on BPC-157 and TB-500 mechanisms, the combination rationale and its missing evidence on why researchers pair the two peptides, the animal-study dose context including half-life and reconstitution, the WADA prohibition status of both peptides, and the full reference list.